Who's Booked On?
Discovering & Developing a New Era of Cardiometabolic Therapeutics
The obesity therapeutics landscape is undergoing a radical expansion, fueled by groundbreaking late-stage trials for Novo Nordisk's amycretin and Metsera's exciting early data for its amylin-targeting shot. Underscored by new insights into Eli Lilly's tirzepatide's cardiovascular benefits, the field is witnessing a paradigm shift beyond GLP-1s to novel mechanisms, combination therapies, and oral formulations. This new era of innovation promises wider accessibility and improved patient outcomes, makes the 2nd Innovation in Obesity Therapeutics Summit the essential forum for accelerating the next wave of treatment.
This year, we're diving deep into game-changing potential of novel mechanisms of action, muscle-preserving strategies, and multi-agonist therapies. Hear from the titans of the pharmaceutical industry, including Novo Nordisk, Eli Lilly and Boehringer Ingelheim, as well as innovative biotechs like Veru, Supercede Therapeutics, and Rivus Pharmaceuticals, who will share their groundbreaking research and strategies. The pressure is on to continue work on developing best-in-class treatments that transform patient lives.
Don't miss this pivotal opportunity to network with 60+ leading scientists and drug development experts in the field of obesity, forge crucial collaborations, and be part of the solution. The future of obesity therapeutics is being written now – be a part of it!
"Broad perspective on the future of obesity treatments from both scientific presenters and service providers"
Adipo Therapeutics
Explore the Full Event Guide
- 60+ Leading Scientists & Drug Development Experts Sharing Groundbreaking Research & Strategies
- 1 Pre-Conference Focus Day
- 10+ Hours of Networking with 60+ Likeminded Obesity Peers
World-Class Speaker Faculty Includes:
Previously Attending Companies Include:
Partnership Opportunities
Partnering with the 2nd Innovation in Obesity Therapeutics Summit is more than just a branding opportunity, it’s a strategic move to exceed your business development goals and position your solutions at the center of obesity therapeutics transformation.
In short, here’s your business case for sponsoring:
- Stay ahead of the curve and competition with a deep dive into novel mechanisms of action, from multi-agonists to gene therapies, that are designed to deliver superior efficacy and address critical issues like muscle preservation and patient adherence
- Get a roadmap for success and position your company as the go-to service provider within expert-led sessions on preclinical translation, clinical development, and how to accelerate your candidate from bench to bedside
- Connect with the decision makers within the obesity space at the Summit’s targeted networking opportunities and meet leaders from companies including Eli Lilly, Boehringer Ingelheim, and Novo Nordisk to forge the collaborations and new business
Official Partners
Explore Related Events
